Overall, our study not only defines a mechanism by which the crosstalk of PML-RARα/PPARγ/TRIB3 contributes to the abnormal lipid metabolism associated with APL but also provides a rationale for the combination of ATRA/arsenic with PPAR activator for APL therapy. The gene discussed is RARA; the disease is acute promyelocytic leukemia.